ketorolac has been researched along with Eye Pain in 4 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Eye Pain: A dull or sharp painful sensation associated with the outer or inner structures of the eyeball, having different causes.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The study drug was significantly better than the vehicle and ketorolac in maintaining mydriasis (least-squares mean differences 0." | 5.24 | Intracameral ketorolac and phenylephrine effect on intraoperative pupil diameter and postoperative pain in cataract surgery. ( Donnenfeld, ED; Jackson, MA; Whitaker, JS; Wittpenn, J, 2017) |
| "The patients were asked to score the postoperative pain in each eye with a visual analog scale at 6, 18, 24, 36, 48, 72, and 96 hours." | 2.79 | Comparison of analgesic effect of preoperative topical diclofenac and ketorolac on postoperative pain after photorefractive keratectomy. ( Hong, JP; Im, CY; Kim, EK; Kim, TI; Nam, SM; Seo, KY; Yoon, S, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Donnenfeld, ED | 2 |
| Whitaker, JS | 1 |
| Jackson, MA | 1 |
| Wittpenn, J | 1 |
| Hong, JP | 1 |
| Nam, SM | 1 |
| Im, CY | 1 |
| Yoon, S | 1 |
| Kim, TI | 1 |
| Kim, EK | 1 |
| Seo, KY | 1 |
| Hovanesian, JA | 1 |
| Sheppard, JD | 1 |
| Trattler, WB | 1 |
| Gayton, JL | 1 |
| Malhotra, RP | 1 |
| Schaaf, DT | 1 |
| Ng, E | 1 |
| Dunn, SH | 1 |
| Nichamin, LD | 1 |
| Hardten, DR | 1 |
| Raizman, MB | 1 |
| Trattler, W | 1 |
| Rajpal, RK | 1 |
| Alpern, LM | 1 |
| Felix, C | 1 |
| Bradford, RR | 1 |
| Villanueva, L | 1 |
| Hollander, DA | 1 |
| Schiffman, RM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00521456] | Phase 3 | 263 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [NCT00524264] | Phase 3 | 248 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pupil area post-irrigation and aspiration (NCT00521456)
Timeframe: Day 0
| Intervention | millimeters squared (mm²) (Mean) |
|---|---|
| Ketorolac Solution | 37.9 |
| Vehicle Solution | 36.5 |
Measured on a scale of 0-4 (0 = none, 4 = intolerable) (NCT00521456)
Timeframe: Day 1
| Intervention | % of participants with a score of 0 (Number) |
|---|---|
| Ketorolac Solution | 70.0 |
| Vehicle Solution | 38.5 |
Anterior chamber inflammation is the sum of biomicroscopic cell and flare; each measured on a scale of 0-4 (Flare: 0 = no flare, 4 = intense flare / Cell: 0 = no cells, 4 = >50 cells) (NCT00521456)
Timeframe: Day 14
| Intervention | % of participants with a score of 0 (Number) |
|---|---|
| Ketorolac Solution | 58.0 |
| Vehicle Solution | 27.3 |
Patients with ≥ 3 line improvement in visual acuity (NCT00521456)
Timeframe: Change from baseline at Day 14
| Intervention | Percentage of patients with ≥ 3 lines (Number) |
|---|---|
| Ketorolac Solution | 56.9 |
| Vehicle Solution | 36.3 |
Pupil area post-irrigation and aspiration (NCT00524264)
Timeframe: Day 0
| Intervention | millimeters squared (mm²) (Mean) |
|---|---|
| Ketorolac Solution | 41.8 |
| Vehicle Solution | 41.1 |
Measured on a scale of 0-4 (0 = none, 4 = intolerable) (NCT00524264)
Timeframe: Day 1
| Intervention | % of participants with a score of 0 (Number) |
|---|---|
| Ketorolac Solution | 75.0 |
| Vehicle Solution | 41.0 |
Anterior chamber inflammation is the sum of biomicroscopic cell and flare; each measured on a scale of 0-4 (Flare: 0 = no flare, 4 = intense flare / Cell: 0 = no cells, 4 = >50 cells) (NCT00524264)
Timeframe: Day 14
| Intervention | % of participants with a score of 0 (Number) |
|---|---|
| Ketorolac Solution | 46.3 |
| Vehicle Solution | 25.6 |
Patients with ≥ 3 line improvement in visual acuity (NCT00524264)
Timeframe: Change from baseline at Day 14
| Intervention | Percentage of patients with ≥ 3 lines (Number) |
|---|---|
| Ketorolac Solution | 59.5 |
| Vehicle Solution | 46.2 |
4 trials available for ketorolac and Eye Pain
| Article | Year |
|---|---|
Intracameral ketorolac and phenylephrine effect on intraoperative pupil diameter and postoperative pain in cataract surgery.
Topics: Cataract Extraction; Eye Pain; Humans; Ketorolac; Mydriasis; Mydriatics; Pain, Postoperative; Phenyl | 2017 |
Comparison of analgesic effect of preoperative topical diclofenac and ketorolac on postoperative pain after photorefractive keratectomy.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Corneal Stroma; Diclofenac; | 2014 |
Intracameral phenylephrine and ketorolac during cataract surgery to maintain intraoperative mydriasis and reduce postoperative ocular pain: Integrated results from 2 pivotal phase 3 studies.
Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Anti-Inflammatory Agents, Non-Steroidal; Double-Bl | 2015 |
Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Eye Pa | 2011 |
Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Eye Pa | 2011 |
Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Eye Pa | 2011 |
Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Eye Pa | 2011 |